

To,

Date: 10.08.2022

1. BSE Limited P.J. Towers, Dalal Street, Mumbai - 400 001	2. Metropolitan Stock Exchange of India Limited 205(A), 2 nd Floor, Piramal Agastya Corporate Park, Kamani Junction, LBS Road, Kurla (West), Mumbai-400 070
--	---

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 10.08.2022

Ref: Scrip Code 539267, DRHABEEB

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Dr Habeebullah Life Sciences Limited held on Wednesday, 10.08.2022 at 3:30 p.m. at the Registered office of the Company at 6-3-354/13/B2, Flat. No. B2, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad-500034, Telangana, the following were considered and approved:

1. Un-Audited financial results for the quarter ended 30.06.2022. **(Enclosed)**
2. Limited Review Report as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the quarter ended 30.06.2022. **(Enclosed)**
3. The change of name of the Company from Dr Habeebullah Life Sciences Limited to Samsrita Labs Limited subject to the approval of the shareholders and other relevant authorities.
4. Directors' reports for the financial year 2021-22.
5. Convening of 26th Annual General Meeting (AGM) of the Company on Saturday, 17th September, 2022 at 11:00 AM through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM"), in accordance with the relevant circulars issued by the Ministry of Corporate Affairs ('MCA') and the Securities and Exchange Board of India ('SEBI').
6. Pursuant to Regulation 42 of Listing Regulations, the Register of Members and Share Transfer Books of the Company will remain closed from 10.09.2022 to 17.09.2022 (both days inclusive) for the purpose of 26th AGM.



Dr Habeebullah Life Sciences Ltd

Regd. Off & Corp Off : 6-3-354/13/B2,, Suryateja Apartments, Hindinagar, Punjagutta, Hyderabad-500082

.CIN No.: L85110TG1996PLC099198. Email: cs@drhsl.com, info@drhsl.com, pcproductsindia@gmail.com

Contact No.: 9490424639, Website : www.drhsl.com

The meeting concluded at 5:00 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours sincerely,

For Dr Habeebullah Life Sciences Limited



K. Krishnam Raju
Whole-time Director
DIN: 00874650

Enact: as above

Dr Habeebullah Life Sciences Ltd

Regd. Off & Corp Off : 6-3-354/13/B2,, Suryateja Apartments, Hindinagar, Punjagutta, Hyderabad-500082

.CIN No.: L85110TG1996PLC099198. Email: cs@drhsl.com, info@drhsl.com, pcproductsindia@gmail.com

Contact No.: 9490424639, Website : www.drhsl.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER I ENDED 30TH JUNE, 2022

(INR In Lakhs)

		Quarter Ended			Previous Year Ended 31-03-2022
		3 Months Ended 30/6/2022	Preceding 3 Months Ended 31/03/2022	Corresponding 3 months ended in previous year 30/06/2021	
		UnAudited	Audited	UnAudited	
I	Revenue from Operations	-	2.25	-	2.25
II	Other Income	4.40	178.44	3.95	190.62
III	Total Revenue (I+II)	4.40	180.69	3.95	192.87
IV	Expenses				
	Purchases	-	2.16	-	2.16
	Cost of Material Consumed	-	-	-	-
	Changes in inventories	-	12.92	-	12.92
	Employee benefits expense	2.76	5.28	0.66	11.47
	Depreciation and Amortisation expense	0.08	0.13	0.13	0.54
	Other Expenses	5.99	2.33	7.57	15.94
	Total Expenses	8.83	22.82	8.36	43.03
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(4.43)	157.87	(4.41)	149.84
VI	Exceptional Items	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(4.43)	157.87	(4.41)	149.84
VIII	Tax Expense:				
	Current Tax	-	-	-	-
	Deferred Tax	-	-	-	-
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(4.43)	157.87	(4.41)	149.84
X	Profit/ (Loss) from discontinuing operations	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-
XIII	Profit/ (Loss) for the period (IX+XII)	(4.43)	157.87	(4.41)	149.84
XIV	Other Comprehensive Income				
	A) (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss	-	-	-	-
	(B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to	-	-	-	-
XV	period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(4.43)	157.87	(4.41)	149.84
XVI	Comprehensive Income attributable to Non Controlling Interest	-	-	-	-
XVII	Comprehensive Income attributable to Owners of the company	(4.43)	157.87	(4.41)	149.84
XVIII	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)				
	1) Basic	(0.03)	1.07	(0.03)	1.01
	2) Diluted	(0.03)	1.07	(0.03)	1.01
XIX	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)				
	1) Basic	-	-	-	-
	2) Diluted	-	-	-	-
XX	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)				
	1) Basic	(0.03)	1.07	(0.03)	1.01
	2) Diluted	(0.03)	1.07	(0.03)	1.01
XXI	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1,480.87	1,480.87	1,480.87	1,480.87



Notes:

1. The above unaudited financial results for the quarter ended 30th June 2022 have been subject to a limited review by the statutory auditors, and reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Wednesday 10th August 2022.
2. The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
3. The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
4. The Previous year's/quarter's figures have been regrouped/rearranged wherever necessary, for the purpose of comparison.

For DR HABEEBULLAH LIFE SCIENCES LIMITED




K Krishnam Raju

Executive Chairman(DIN 00874650)

Place : Hyderabad

Date: 10/08/2022





A.M. REDDY & D.R. REDDY

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on unaudited Quarterly Financial results of Dr Habeebullah Life Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended


To,
The Board of Directors,
Dr Habeebullah Life Sciences Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Dr Habeebullah Life Sciences Limited ("the Company") for the quarter ended June 30, 2022 and year to date results for the period April 01, 2022 to June 30, 2022 ("the Statement ") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We Conducted our review of the statement in accordance with the Standard of Review engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit Opinion.




4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A M Reddy & D R Reddy
Chartered Accountants
FRN 0090685


D. Rama Krishna Reddy
Partner

M.No.209211

UDIN: 22209211AOTHUI1918



Place : Hyderabad

Date: 10/08/2022